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Abstract
Purpose This study aimed to evaluate the applicability of the
principles and informed consent form (ICF) template pro-
posed by the Strategic Initiative for Developing Capacity in
Ethical Review (SIDCER) in a clinical pharmacokinetic study
by comparing the volunteers’ understanding of the enhanced
ICF (developed based on the SIDCER methodology) and the
conventional ICF (which was previously approved by local
Ethics Committee and used in the clinical study).
Methods A total of 550 volunteers were randomly assigned to
read either the enhanced ICF or the conventional ICF (1:1) in a
mock informed consent approach and subsequently per-
formed the post-test questionnaire. The primary endpoint
was the proportion of the participants who had the post-test
score of ≥80 %; the secondary endpoints were the total score
of the post-test, the score of the categorized ICF elements, and
time spent for participation.
Results The proportion of the participants in the enhanced
ICF group who achieved the primary endpoint was signifi-
cantly higher than the conventional ICF group (82.2 % vs.
60.4 %, p < 0.001). The participants in the enhanced ICF
group obtained higher scores and spent less time in reading
the given ICF and answering the post-test than those in the
conventional ICF group (total score 19/21 vs. 18/21,
p < 0.001; time spent 20 min vs. 25 min, p < 0.001).
Conclusion The enhanced ICF improved the understanding
of the participants in this study. This demonstrates the appli-
cability of the SIDCER ICF principles and its template in the
development of an enhanced ICF for improving the quality of
ICFs and subjects’ understanding in clinical research.
Trial registration: TCTR20140727001
Keywords Informed consent . Clinical research . Clinical
study . Healthy subjects . Healthy volunteers . Understanding
Introduction
The subjects’ limited understanding of trial information has
been a continuing source of concern especially in non-
therapeutic studies involving healthy volunteers. After the in-
cident of the TGN1412 study, there has been an increasing
concern regarding the validity of informed consent in healthy
volunteers in phase I studies. All healthy volunteers who re-
ceived an intervention in the TGN1412 study ended up in the
intensive care unit [1]. Investigations of how much the volun-
teers understood the risks involved in the study show that the
informed consent form (ICF) was extensively long (13 pages),
lacked many essential elements, and made liberal use of com-
plex language [2]. The volunteers did not have a real under-
standing of the risks that would be involved in the study or
recognize the risks when participating in the study [3]. This
study highlights concerns about the safety of healthy volun-
teers in clinical trials. Comprehension of research subjects,
particularly concerning their rights and the risks involved in
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clinical research, has become a matter of paramount impor-
tance [4, 5]. Literature reviews demonstrate limited under-
standing of fundamental trial aspects among healthy research
volunteers, even experienced ones who were enrolled in the
long-duration clinical trials [5–7]. Some of them could not
even name the drug they were taking or recall any side
effects of that drug [6]. These cases call into question the
quality and validity of informed consent currently being
practiced in clinical research.
An ICF is a required document in clinical studies, which
provides information of a particular study to potential research
subjects and documents an individual subject’s voluntary con-
sent to participate in research. To date, the quality of ICFs used
in clinical studies is still problematic due mainly to extensive
length [8–10], chaotic structure, and overly technical language
[11, 12]. These potentially reduce the subject’s ability to thor-
oughly read and understand the information provided therein
[13], thus compromising the ethical principle of respect for
persons [14]. Additionally, information essential for a sub-
ject’s decision-making is sometimes missing in many ICFs
[15]. Improvement of the quality of ICFs in clinical trials is
thus necessary for ethical research conduct. For decades, ICFs
have been extensively refined and two systematic reviews
demonstrate the effectiveness of an enhanced or simplified
ICF in improving subjects’ understanding in clinical research
[16, 17].
Recently, the Strategic Initiative for Developing Capacity
in Ethical Review (SIDCER), an organization launched by the
Special Programme for Tropical Disease Research, World
Health Organization in 2001, has proposed the SIDCER ICF
principles and template for ICF development. The concept
and structure of the SIDCER ICF have been refined and final-
ized in collaboration with researchers and Ethics Committee
members mainly from the Forum of Ethical Review Commit-
tees in the Asian and Western Pacific region (FERCAP). In
short, the SIDCER ICF consists of three principles: (1) com-
pleteness of the mandatory ICF content required by interna-
tional ethics guidelines and regulations, (2) concise informa-
tion provision which is relevant to a subject’s decision-making
and local context, and (3) use of simplified means to effective-
ly convey relevant information to the target population. The
SIDCER ICF template for clinical trials has been designed to
guide the development of an ICF based on the SIDCER ICF
principles (presented in the 14th FERCAP Conference,
Tagaytay, Philippines, 2014). Validation of the SIDCER ICF’s
applicability and effectiveness in a variety of clinical studies
with different designs is needed. Although the concept is uni-
versal, the application and validation must be done in a local
language as it plays a major role in the comprehension of
research subjects in a reference setting and context.
The present study is an empirical study to test the SIDCER
ICF’s applicability and effectiveness in Thai and to evaluate
the understanding of Thai volunteers. The SIDCER ICF
methodology was applied to a clinical pharmacokinetic (PK)
drug-drug interaction (DDI) study involving healthy subjects,
and the local volunteers’ understanding between the enhanced
(SIDCER) ICF and the conventional ICF was compared using
a randomized-controlled design.
Methods
This study was an open-label, randomized-controlled study of
the two different ICF interventions (1:1), i.e., the enhanced
ICF and the conventional ICF, using a post-test questionnaire
as an assessment tool. The clinical study protocol of the PK
DDI study entitled BEffect of curcuminoids on the blood level
of digoxin in healthy male volunteers^ (Trial Registration
Number: ChiCTR-TTRCC-14004645) was used to be the
core information for ICF development.
The enhanced informed consent form
Following the SIDCER ICF principles and template, the en-
hanced ICF was developed (in Thai) based on the
abovementioned clinical study protocol. In close observation
of the first SIDCER ICF principle, the study protocol was
reviewed and the essential information in regard to compli-
ance with internationally recognized regulatory ICF require-
ments are selected and present in the enhanced ICF. To limit
the contents and length of the enhanced form in accordance
with the second SIDCER ICF principle, the information in the
study protocol was carefully analyzed and summarized, and
only relevant information to a subject’s decision-making on
research matters was used for ICF development. The refined
information was then transformed into a narrative and illustra-
tive format and appropriately inserted into the SIDCER ICF
template (where the third SIDCER ICF principle is applied)
using local lay language with reference to local context.
A four-page enhanced ICF containing 21 required elements
was successfully developed (Table 1). It was then reviewed by
the principal investigator of the PK DDI study (NH) to ensure
the accuracy of information and by two independent local
laypersons to ensure the use of the simplest terms with refer-
ence to local context.
The conventional informed consent form
The original ICF (in Thai) used in the abovementioned PK
DDI study was considered as a conventional ICF in the pres-
ent ICF study. This ICF was previously approved by the Re-
search Ethics Committee of the Faculty of Medicine, Chiang
Mai University, 2 years prior to the development of the
SIDCER ICF, and it was used in the real informed consent
process of that study. It had seven pages containing 15 re-
quired elements (Table 1).
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The post-test questionnaire
The post-test questionnaire (in Thai) consisted of 21 short case
studies where each case study was designed to illustrate a
common practical situation of one element required, followed
by a question with three possible answers. It was used as an
assessment tool to determine the volunteers’ understanding of
each required element after they read a given ICF. All case
studies and answer choices were also reviewed and corrected
by the principal investigator of the PK DDI study (NH) and
two independent laypersons.
Study endpoints
The primary endpoint was the proportion of the participants
who had the post-test score of more than 80 %. The secondary
endpoints were the total score of the post-test, the score of
each category of elements required (Table 1), and time spent
for reading a given ICF and doing the post-test questionnaire.
Sample size determination
The estimated sample size was calculated using G*pow-
er 3.1.9.2 for Windows. The z-test to detect the 10 %
difference between two independent proportions of the
primary endpoint (p1 = 0.85 and p2 = 0.75) was ap-
plied, with the precision and confidence level of 95 %
(α = 0.05) and 80 % power (1 − β = 0.80), using
continuity correction with allocation ratio of 1. A sam-
ple size of at least 269 subjects is adequate for each
group.
Study procedure
Volunteers (age > 18) who can read and write Thai were
recruited from universities, colleges, cafeterias, hospitals,
and markets in Chiang Mai, Thailand. Individuals who
had no time to read the entire ICF and do the post-test
questionnaire were excluded. All processes were done in
an anonymous manner using a subject unique number.
Table 1 The enhanced ICF and
the conventional ICF Enhanced ICF Conventional ICF
Number of pages 4 7
Number of required elements provided 21 15
General items
Recognition that this is research ✓ ✓
Subject’s responsibility ✓ ✓
Confidentiality of records ✓ ✓
Who can access the data ✓ Not stated
Research contact person(s) ✓ ✓
Rights of the subject
Right to refuse ✓ ✓
Right to withdraw ✓ ✓
Consequences of withdrawal ✓ Not stated
Right to receive new relevant information ✓ Not stated
Scientific aspects
Subject eligibility ✓ ✓
Number of subjects required ✓ ✓
Purpose of the study ✓ ✓
Trial treatment ✓ ✓
Trial procedures ✓ ✓
Duration of the subject’s participation ✓ Not stated
Ethical aspects
Foreseeable risks ✓ ✓
Expected direct and/or indirect benefits ✓ Not cleara
Participant termination criteria ✓ Not stated
Prorated payment for participation ✓ ✓
Anticipated expenses ✓ ✓
Compensation for injury ✓ ✓
a BNo direct benefit from study participation^ was not stated
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The study protocol and all related documents were ap-
proved by the Research Ethics Committee of the Faculty
of Medicine, Chiang Mai University. All procedures per-
formed in this study were in accordance with the ethical
standards of the institutional and national research com-
mittee and with the 2013 Helsinki declaration. Written
informed consent was obtained from all individual partic-
ipants prior to the enrollment of the study. This study was
registered as TCTR20140727001 via the Thai Clinical
Trial Registry.
There were two main processes in this study: (1) the pro-
cess of reading a given ICF and (2) the process of completing
the post-test questionnaire. The participants were randomly
assigned to read either the enhanced ICF or the conventional
ICF (Fig. 1). After receiving an ICF (the enhanced ICF or the
conventional ICF), individuals were given an unlimited time
to read the given ICF. The post-test questionnaire was then
distributed, and individuals were allowed to keep and consult
the ICF while completing the questionnaire. If any question
was unclear or no information was given by the ICF, individ-
uals could mark down Bno answer^ or Bunable to answer^ in
the questionnaire. The time spent on the two processes was
recorded.
Data analysis
Of the three possible answers in each question, there was only
one correct answer, counting as a score of 1, making the total
score 21. Incorrect answer, no answer or unable to answer in
each question was counted as a score of 0. The chi-square test
was applied for the comparison of the difference of nominal
data between the two groups. The interval data were analyzed
by nonparametric statistics and presented in a median
(interquartile) since none of them were normally distributed.
Subgroup analyses were performed by applying the chi-
square test to determine the impact of genders (male and fe-
male), generations (generation Y, participants who were born
between 1982 and 2000; generation X, participants who were
born between 1965 and 1981; and baby boomers, participants
who were born between 1946 and 1964) [18] and educational
levels (level 1, high school or lower; level 2, bachelor degree
or equivalent, diploma degree, or undergraduate level; and
level 3, master/doctoral degree or equivalent, or graduate lev-
el) on the primary outcome. A statistical significance was set
at α = 0.05 for all tests. Statistical analysis was performed
using standard statistical software (SPSS version 22.0).
Figures were generated using GraphPad Prism ver. 5.0.
Fig. 1 Study procedure
Table 2 Demographic data of the





Generation Y 173 195
Generation X 72 58
Baby boomers 30 22
Educational level
Level 1 44 43
Level 2 208 210
Level 3 23 22
Data represent the number of participants. Generation was divided into three subgroups: (1) generation Y
includes participants who were born between 1982 and 2000; (2) generation X includes participants who were
born between 1965 and 1981; and (3) baby boomers includes participants who were born between 1946 and
1964. Educational level was divided into three sub-levels: level 1 represents high school level or lower; level 2
represents bachelor degree or equivalent, diploma degree, or undergraduate level; and level 3 represents master/
doctoral degree or equivalent, or graduate level.
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Results
A total of 550 participants, aged 18–67 years (median
age = 24 years), were enrolled: 62 % were female;
66.9 % were under generation Y; and 76 % had educa-
tional level 2. Their demographic data are shown in
Table 2.
The distribution of the post-test score of the participants in
each group is shown in Fig. 2. Eighty-three participants
(30.2 %) in the enhanced ICF group and 26 participants
(9.5 %) in the conventional ICF group achieved the perfect
score (RR 3.192, 95 % CI 2.124–4.798, p < 0.001). The pro-
portion of the participants in the enhanced ICF group who
achieved the primary endpoint was significantly higher than
that in the conventional ICF group (82.2 % vs. 60.4 %, RR
1.361, 95 % CI 1.219–1.520, p < 0.001) (Fig. 3). Subgroup
analyses by gender, generation, and educational level
demonstrated that all but the participants in the baby boomers
generation and participants who had educational level 3 fa-
vored the enhanced ICF (Fig. 3). The proportion of the partic-
ipants in the enhanced ICF group who correctly answered
each item in the post-test questionnaire was compared to that
in the conventional ICF group: significant differences were
seen in 13 out of 21 items (Fig. 4).
The assessment of the secondary endpoints showed that the
total score of the post-test and the score of each category in the
enhanced ICF group were significantly higher than those in
the conventional ICF group (total score 19 vs. 18, p < 0.001;
score of general items 5 vs. 4, p < 0.001; score of rights of the
subject 4 vs. 4, p = 0.023; score of scientific aspects 6 vs. 5,
p < 0.001; score of ethical aspects 5 vs. 4, p < 0.001). The time
spent by the participants in the enhanced ICF group was sig-
nificantly lesser than that in the other group (20 min vs.
25 min, p < 0.001).
Fig. 2 The distribution of the
post-test score of the participants.
Black bars represent the enhanced
ICF group; gray bars represent
the conventional ICF group
Fig. 3 Proportions of the participants whose post-test score was
satisfied according to the 80 % passing level (the primary endpoint). #
Relative risk is the ratio derived from the proportion of the participants in
the enhanced ICF group whose post-test scores were satisfied according
to the 80% passing level divided by that of the conventional ICF group. *
Chi-square test
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Discussion
The present study demonstrates the applicability of the SIDCER
ICF and its template in the development of an enhanced ICF for
the clinical PK trial and its effectiveness in improving the par-
ticipants’ understanding of information related to the trial.
Higher proportions of the participants who read the enhanced
ICF obtained the satisfactory level of understanding at 80 % and
perfect score in the post-test questionnaire than those who read
the conventional ICF (82.2% vs. 60.4 %, p < 0.001, and 30.2 %
vs. 9.5 %, p < 0.001, respectively). The participants in the en-
hanced ICF group spent less time but achieved higher scores on
Fig. 4 Proportions of the participants who correctly answered each item
in the post-test questionnaire. # Relative risk is the ratio derived from the
proportion of the participants in the enhanced ICF group who correctly
answered each item in the post-test questionnaire divided by that of the
conventional ICF group. * Chi-square test
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the post-test when compare to those in the conventional ICF
group (time spent 20 vs. 25, p < 0.001; total score 19 vs. 18,
p < 0.001).
This study was the first study conducted to validate the
applicability and effectiveness of the SIDCER ICF, using a
randomized-controlled design. The results indicate that short-
ening the length of an ICF is possible while retaining all es-
sential elements in a concise manner and that the SIDCER ICF
template is applicable to a clinical PK study and its application
is effective in this group of population. Since literature re-
views demonstrate the mixed results of other ICF studies
using other enhanced forms in improving research subjects’
understanding [19–25], further studies on the application of
the SIDCER ICF and evaluation of subjects’ understanding in
a variety of study designs, settings, languages, and groups of
population are required.
A closer examination of our results reveals the reasons why
the participants in the enhanced ICF group did better than
those in the conventional group in the post-test questionnaire.
The first reason is that the enhanced ICF presents a complete
set of the information required according to the first SIDCER
ICF principle. Of the 13 questions in which the enhanced ICF
group scored higher (Fig. 4), four items (including who can
access the data, duration of the subject’s participation, expect-
ed direct/indirect benefits, and participant termination criteria)
were not described in the conventional ICF (Table 1). The
second reason is that the enhanced ICF uses an innovative
presentation means in accordance with the third SIDCER
ICF principle to convey relevant information to the target
population. Nine of the 13 items (including research contact
person, right to refuse, right to withdraw, subject eligibility,
number of subjects required, trial procedures, foreseeable
risks, anticipated expenses, and compensation for injury) were
sufficiently presented in both ICFs but the enhanced ICF
group was able to achieve a higher score. Interestingly, there
were two items, including consequences of withdrawal and
right to receive new information, which were not stated in
the conventional ICF; but the proportions of the participants
who correctly answered between the two groups did not show
a statistically significant difference. This could be due to a
practicable drawback of the evaluation tool: a close-ended
question with multiple answer choices gave an individual a
chance to inadvertently give the correct answer [26].
Although most of our data favored the enhanced ICF, there
were two data subgroups that did not fully support our con-
clusion: the participants in the baby boomers generation and
the participants in the educational level 3. Literature points out
that each generation has a difference in perspective and per-
ception [27]. It is possible that the presentation manners, such
as figures or diagrams, used in the SIDCER ICF template
might not be suitable for some generations. The increased
proportion of the participants with optimal understanding by
the enhanced ICF was observed in generation Y and
generation X. Although there was a trend for baby boomers
in the enhanced ICF group to do better, it was not statistically
significantly enough to conclude that the enhanced ICF was
more effective in this generation than the conventional ICF
(83.3 % vs. 63.6 %, p = 0.105). A possible reason for this
result is the small number of subjects in the baby boomers
generation in comparison to the other generations (Table 2),
as we did not control this factor when conducting the study.
With regards to the educational level, although the result in-
dicates that the enhanced ICF increased the proportion of the
participants with optimal understanding in the participants
with educational levels 1 and 2, there was little effect in the
participants with educational level 3 whose understanding lev-
el was high in both groups. This is consistent with the lines of
evidence demonstrating that the educational level is a major
determinant to research subjects’ comprehension [28, 29]. In
research practice, research subjects generally come from var-
ious backgrounds with different educational levels; thus, the
SIDCER ICF could be of value.
It should be noted that this study was performed in a mock
population so that the level of understanding might be either
overestimated, due to the inclusion of only respondents who
were willing to read a given ICF, or underestimated, owing to
their limited concern for the information regarding study par-
ticipation. Studies involving real research subjects of clinical
studies could provide stronger evidence to support the effec-
tiveness of the SIDCER ICF in enhancing subjects’ under-
standing of ICFs.
Conclusions
Understanding of the participants in this study was improved
by the enhanced ICF developed based on the SIDCER ICF
principles and template. The results of this study demonstrate
the potential of the application of the SIDCER ICF principles
and its template in improving the quality of ICFs and subjects’
understanding in clinical research. Further studies to evaluate
the applicability and effectiveness of the SIDCER ICF in a
variety of clinical studies in different languages and settings
are necessary.
Acknowledgments We thank Ms. Kedsada Ruangsuttinaruparp,
Ms. Chotimanee Kaewserm, Ms. Chompunoot Koonrungsesomboon,
Dr. Sumitra Pongsiri, Mr. Suraphon Wongsathit, Dr. Noppamas
Pipatpiboon, Ms. Rapheephorn Khatsri, Dr. Jirapas Sripetchwandee,
Mr. Tayakorn Puengkrim, Ms. Sujitra Techatoei, and Dr. Kanchana
Koonrungsesomboon for their assistance on the data collection pro-
cess. We thank Prof. Kenji Hirayama for valuable comments on this
study. This study was partially supported by TDR, the Special Pro-
gramme for Research and Training in Tropical Diseases, co-
sponsored by UNICEF, UNDP, the World Bank and WHO, and the
Forum for Ethical Review Committees in the Asian and Western
Pacific region (FERCAP). Dr. Nut Koonrungsesomboon is a recipi-
ent of the scholarship from the Program for Nurturing Global Leaders
Eur J Clin Pharmacol (2016) 72:413–421 419
in Tropical and Emerging Communicable Diseases, Graduate School
of Biomedical Sciences, Nagasaki University.
Authors’ contributions N. Koonrungsesomboon designed the study,
developed the study protocol and related materials, conducted the study,
analyzed the data, interpreted the results, and prepared a drafted manu-
script. S. Teekachunhatean provided the clinical pharmacokinetic study
protocol and the conventional ICF, reviewed the materials, collaborated
the study, analyzed the data, interpreted the results, and provided com-
ments for manuscript improvement. N. Hanprasertpong provided the clin-
ical pharmacokinetic study protocol and the conventional ICF, reviewed
the materials, collaborated the study, and provided comments for manu-
script improvement. J. Laothavorn provided comments and reviewed the
materials, and revised a manuscript. K. Na-Bangchang collaborated the
study, and provided comments for manuscript improvement. J. Karbwang
designed the study, developed the study protocol and related materials,
conducted the study, analyzed the data, interpreted the results, and final-
ized the manuscript.
Compliance with ethical standards
Conflict of interest The authors disclose that there are no conflicts of
interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1 Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A,
Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1
trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J
Med 355(10):1018–1028. doi:10.1056/NEJMoa063842
2 Sugarman J, Levine C (2006) Risk in drug trials. Lancet 368(9554):
2205. doi:10.1016/S0140-6736(06)69881-4
3 Knapp P, Raynor DK, Silcock J, Parkinson B (2009) Performance-
based readability testing of participant materials for a phase I trial:
TGN1412. J Med Ethics 35(9):573–578. doi:10.1136/jme.2008.
026708
4 Arora A, Rajagopalan S, Shafiq N, Pandhi P, Bhalla A, Dhibar DP,
Malhotra S (2011) Development of tool for the assessment of com-
prehension of informed consent form in healthy volunteers partici-
pating in first-in-human studies. Contemp Clin Trials 32(6):814–
817. doi:10.1016/j.cct.2011.05.012
5 Apseloff G, Kitzmiller JP, Tishler CL (2013) Credibility and com-
prehension of healthy volunteers in lengthy inpatient drug studies.
Am J Ther 20(3):257–260. doi:10.1097/MJT.0b013e3182811a9e
6 Fortun P,West J, Chalkley L, Shonde A, Hawkey C (2008) Recall of
informed consent information by healthy volunteers in clinical trials.
QJM 101(8):625–629. doi:10.1093/qjmed/hcn067
7 Fitzgerald DW, Marotte C, Verdier RI, Johnson WD, Pape JW
(2002) Comprehension during informed consent in a less-
developed country. Lancet 360(9342):1301–1302. doi:10.1016/
S0140-6736(02)11338-9
8 Sharp SM (2004) Consent documents for oncology trials: does any-
body read these things? Am J Clin Oncol 27(6):570–575
9 Berger O, Grønberg BH, Sand K, Kaasa S, Loge JH (2009) The
length of consent documents in oncological trials is doubled in
twenty years. Ann Oncol 20(2):379–385. doi:10.1093/annonc/
mdn623
10 Kass NE, Chaisson L, Taylor HA, Lohse J (2011) Length and com-
plexity of US and international HIV consent forms from federal HIV
network trials. J Gen Intern Med 26(11):1324–1328. doi:10.1007/
s11606-011-1778-6
11 Paasche-Orlow MK, Taylor HA, Brancati FL (2003) Readability
standards for informed-consent forms as compared with actual read-
abi l i ty. N Engl J Med 348(8):721–726. doi:10.1056/
NEJMsa021212
12 Terranova G, FerroM, Carpeggiani C, Recchia V, Braga L, Semelka
RC, Picano E (2012) Low quality and lack of clarity of current
informed consent forms in cardiology: how to improve them.
JACC Cardiovasc Imaging 5(6):649–655. doi:10.1016/j.jcmg.
2012.03.007
13 Beardsley E, Jefford M, Mileshkin L (2007) Longer consent forms
for clinical trials compromise patient understanding: so why are they
lengthening? J Clin Oncol 25(9):e13–e14. doi:10.1200/JCO.2006.
10.3341
14 The Belmont Report: ethical principles and guidelines for the pro-
tection of human subjects of research (1979). U.S. Government
Printing Office, Washington, D.C. 20402.
15 Malik L, Mejia A (2014) Informed consent for phase I oncology
trials: form, substance and signature. J Clin Med Res 6(3):205–208.
doi:10.14740/jocmr1803w
16 Nishimura A, Carey J, Erwin PJ, Tilburt JC, Murad MH,
McCormick JB (2013) Improving understanding in the research
informed consent process: a systematic review of 54 interventions
tested in randomized control trials. BMCMed Ethics 14:28. doi:10.
1186/1472-6939-14-28
17 Dunn LB, Jeste DV (2001) Enhancing informed consent for re-
search and treatment. Neuropsychopharmacology 24(6):595–607.
doi:10.1016/S0893-133X(00)00218-9
18 Lancaster LC, Stillman D (2002) When generations collide. Harper
Collins, New York
19 Corneli AL, Sorenson JR, Bentley ME, Henderson GE, Bowling
JM, Nkhoma J, Moses A, Zulu C, Chilima J, Ahmed Y, Heilig
CM, Jamieson DJ, van der Horst C, Breastfeeding Antiretroviral,
and Nutrition Informed Consent Study Group (2012) Improving
participant understanding of informed consent in an HIV-
prevention clinical trial: a comparison of methods. AIDS Behav
16(2):412–421. doi:10.1007/s10461-011-9977-z
20 Murphy DA, Hoffman D, Seage GR, Belzer M, Xu J, Durako SJ,
Geiger M, Interventions ATNfHA (2007) Improving comprehen-
sion for HIV vaccine trial information among adolescents at risk
of HIV. AIDS Care 19(1):42–51. doi:10.1080/09540120600680882
21 Matsui K, Lie RK, Turin TC, Kita Y (2012) A randomized con-
trolled trial of short and standard-length consent forms for a genetic
cohort study: is longer better? J Epidemiol 22(4):308–316
22 Paris A, Brandt C, Cornu C, Maison P, Thalamas C, Cracowski JL
(2010) Informed consent document improvement does not increase
patients’ comprehension in biomedical research. Br J Clin
Pharmacol 69(3):231–237. doi:10.1111/j.1365-2125.2009.03565.x
23 Enama ME, Hu Z, Gordon I, Costner P, Ledgerwood JE, Grady C,
Teams VCS (2012) Randomization to standard and concise in-
formed consent forms: development of evidence-based consent
practices. Contemp Clin Trials 33(5):895–902. doi:10.1016/j.cct.
2012.04.005
24 Sato K, Watanabe T, Katsumata N, Sato T, Ohashi Y (2014)
Satisfying the needs of Japanese cancer patients: a comparative
study of detailed and standard informed consent documents. Clin
Trials 11(1):86–95. doi:10.1177/1740774513515550
25 Paris A, Nogueira da Gama Chaves D, Cornu C, Maison P, Salvat-
Mélis M, Ribuot C, Brandt C, Bosson JL, Hommel M, Cracowski
420 Eur J Clin Pharmacol (2016) 72:413–421
JL (2007) Improvement of the comprehension of written informa-
tion given to healthy volunteers in biomedical research: a single-
blind randomized controlled study. Fundam Clin Pharmacol 21(2):
207–214. doi:10.1111/j.1472-8206.2007.00472.x
26 MacQueen KM, Chen M, Ramirez C, Nnko SE, Earp KM (2014)
Comparison of closed-ended, open-ended, and perceived informed
consent comprehension measures for a mock HIV prevention trial
among women in Tanzania. PLoS One 9(8):e105720. doi:10.1371/
journal.pone.0105720
27 Mohr NM, Moreno-Walton L, Mills AM, Brunett PH, Promes SB,
Society for Academic EmergencyMedicineAging andGenerational
Issues in Academic Emergency Medicine Task Force (2011)
Generational influences in academic emergency medicine: teaching
and learning, mentoring, and technology (part I). Acad Emerg Med
18(2):190–199. doi:10.1111/j.1553-2712.2010.00985.x
28 Flory J, Emanuel E (2004) Interventions to improve research partic-
ipants’ understanding in informed consent for research: a systematic
review. JAMA 292(13):1593–1601. doi:10.1001/jama.292.13.1593
29 Sanchini V, Reni M, Calori G, Riva E, Reichlin M (2014) Informed
consent as an ethical requirement in clinical trials: an old, but still
unresolved issue. an observational study to evaluate patient’s in-
formed consent comprehension. J Med Ethics 40(4):269–275. doi:
10.1136/medethics-2012-101115
Eur J Clin Pharmacol (2016) 72:413–421 421
